The application of modern technologies to the biology of the normal, dysplastic, and malignant respiratory epithelium promises to allow better prediction of clinical behavior as well as to provide intermediate endpoint biomarkers for therapeutic trials. Major obstacles to the use of molecular genetics in the respiratory epithelium include the difficulty in identifying high-risk individuals for study and the inability to identify dysplastic epithelium for biopsy and the small amount of tissue available. As a result, virtually all studies of the biology of premalignant respiratory epithelium have either utilized screening methods, such as sputum cytology, or epithelial harvest of dysplastic areas in surgical resection specimens from individuals with lung cancer. The former has the disadvantage that limited analysis is possible and the latter approach likely biases analysis toward the examination of more advanced dysplasias which have already demonstrated the potential to progress to carcinoma. During the initial funding period of the University of Colorado SPORE in Lung Cancer, many of the difficulties involved in studying premalignant biology have been addressed through the validation of an appropriate high- risk population for initial screening, the use of fluorescence bronchoscopy for identification of dysplastic epithelium for biopsy, the development of methods for genetic analysis of respiratory epithelium, and the collaboration of several groups of basic scientists with interests in various aspects of the progression to lung cancer. The following hypotheses will now be tested through their respective specific aims with the goal of developing improved methods of early detection and novel approaches to prevention. 1. Fluorescence bronchoscopy improves detection of premalignant dysplasias over white-light bronchoscopy. 2. Exposure to tobacco smoke and other carcinogens modifies the expression of molecular and phenotypic markers in airway epithelium, with more extensive alterations occurring in histologically advanced dysplasias. 3. Dysplastic airway epithelium reverts toward normal with therapeutic intervention, including smoking cessation, chemoprevention, and chemotherapy and/or radiotherapy. 4. Biomarkers identified in premalignant dysplasias and lung tumors have prognostic significance. Each of these hypotheses will be tested through the development and implementation of clinical trial protocols. These studies will allow improvements in definition of high-risk individuals and populations, as well as provide intermediate endpoint biomarkers to accelerate the evaluation of therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-06
Application #
6269581
Study Section
Project Start
1998-05-01
Project End
1999-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770

Showing the most recent 10 out of 435 publications